Humacyte, Inc. (NASDAQ:HUMA) Receives $13.71 Consensus Price Target from Analysts

Humacyte, Inc. (NASDAQ:HUMA) has received a consensus rating of “Buy” from the eight ratings firms that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $13.71.

HUMA has been the topic of several analyst reports. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price (up previously from $12.00) on shares of Humacyte in a research note on Friday, December 20th. D. Boral Capital reiterated a “buy” rating and issued a $25.00 target price on shares of Humacyte in a research note on Tuesday, January 21st. BTIG Research reiterated a “buy” rating and issued a $10.00 target price on shares of Humacyte in a research note on Friday, October 18th. Piper Sandler set a $6.00 target price on Humacyte and gave the company a “neutral” rating in a research note on Friday, October 18th. Finally, TD Cowen reiterated a “buy” rating and issued a $10.00 target price on shares of Humacyte in a research note on Friday, October 18th.

Insider Transactions at Humacyte

In related news, CEO Laura E. Niklason sold 811,172 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $4.44, for a total value of $3,601,603.68. Following the sale, the chief executive officer now owns 2,419,712 shares in the company, valued at $10,743,521.28. This represents a 25.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Brady W. Dougan sold 427,459 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total value of $1,855,172.06. Following the completion of the sale, the director now owns 1,992,253 shares in the company, valued at approximately $8,646,378.02. This represents a 17.67 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,500,000 shares of company stock worth $6,606,799. Insiders own 11.20% of the company’s stock.

Institutional Investors Weigh In On Humacyte

A number of large investors have recently bought and sold shares of the company. Endowment Wealth Management Inc. boosted its position in Humacyte by 3.6% in the fourth quarter. Endowment Wealth Management Inc. now owns 104,108 shares of the company’s stock valued at $526,000 after buying an additional 3,590 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in Humacyte by 18.8% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 27,282 shares of the company’s stock valued at $138,000 after acquiring an additional 4,327 shares during the period. Rhumbline Advisers lifted its holdings in Humacyte by 4.6% in the fourth quarter. Rhumbline Advisers now owns 114,455 shares of the company’s stock valued at $578,000 after acquiring an additional 5,005 shares during the period. Teacher Retirement System of Texas lifted its holdings in Humacyte by 25.3% in the fourth quarter. Teacher Retirement System of Texas now owns 26,200 shares of the company’s stock valued at $132,000 after acquiring an additional 5,293 shares during the period. Finally, Private Advisor Group LLC lifted its holdings in Humacyte by 1.8% in the third quarter. Private Advisor Group LLC now owns 373,110 shares of the company’s stock valued at $2,030,000 after acquiring an additional 6,510 shares during the period. Hedge funds and other institutional investors own 44.71% of the company’s stock.

Humacyte Price Performance

HUMA opened at $3.92 on Friday. The business’s 50-day moving average is $4.50 and its two-hundred day moving average is $5.32. Humacyte has a 1 year low of $2.81 and a 1 year high of $9.97. The firm has a market capitalization of $493.37 million, a PE ratio of -2.93 and a beta of 1.30.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.